Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Autolus Therapeutics plc

Autolus Therapeutics plc (AUTL) Stock Overview

Explore Autolus Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.

AUTL●NASDAQ
HealthcareBiotechnology
$1.94
$0.02(1.04%)
U.S. Market opens in 10h 15m

Autolus Therapeutics plc (AUTL)

Meyka AI Score

Z

Key Financials

Market Cap516.3M
P/E Ratio-1.82
EPS (TTM)$-1.09
ROE-1.79%
Fundamental Analysis

AI Price Forecasts

1 Month$2.20
3 Months$1.57
1 Year Target$1.56

AUTL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Autolus Therapeutics plc (NASDAQ: AUTL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Autolus Therapeutics plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of AUTL on the NASDAQ shows an RSI of 43.22, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $1.56 for the NASDAQ listing.

Key metrics behind Autolus Therapeutics plc's NASDAQ-traded stock include a P/E ratio of -1.82 and a market capitalization of 516.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of AUTL on the NASDAQ.

Price Performance (NASDAQ: AUTL)

1-Day Change
1.04%
5-Day Change
-2.02%
1-Month Change
-15.28%
3-Month Change
28.48%
6-Month Change
33.79%
Year-to-Date (YTD) Change
-2.51%
1-Year Change
42.65%
3-Year Change
-30.96%
5-Year Change
-69.64%
All-Time (Max) Change
-92.24%

Contact Information

https://www.autolus.com
44 20 3829 6230
The MediaWorks, London, GL, W12 7FP

Company Facts

7,520 Employees
IPO DateJun 22, 2018
CountryGB
Actively Trading

Frequently Asked Questions